Targeting active sites of inflammation using inherent properties of tissue-resident mast cells
Source abstract
Abstract
Mast cells play a pivotal role in initiating and directing host's immune response. They reside in tissues that primarily interface with the external environment. Activated mast cells respond to environmental cues throughout acute and chronic inflammation through releasing immune mediators via rapid degranulation, or long-term de novo expression. Mast cell activation results in the rapid release of a variety of unique enzymes and reactive oxygen species. Furthermore, the increased density of mast cell unique receptors like mas related G protein-coupled receptor X2 also characterizes the inflamed tissues. The presence of these molecules (either released mediators or surface receptors) are particular to the sites of active inflammation, and are a result of mast cell activation. Herein, the molecular design principles for capitalizing on these novel mast cell properties is discussed with the goal of manipulating localized inflammation. STATEMENT OF SIGNIFICANCE: Mast cells are immune regulating cells that play a crucial role in both innate and adaptive immune responses. The activation of mast cells causes the release of multiple unique profiles of biomolecules, which are specific to both tissue and disease. These unique characteristics are tightly regulated and afford a localized stimulus for targeting inflammatory diseases. Herein, these important mast cell attributes are discussed in the frame of highlighting strategies for the design of bioresponsive functional materials to target regions of inflammations.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Mast cells and histamine · Asthma and respiratory diseases · Click Chemistry and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Mast-cell responses to pathogens10.1038/nri1460 ↗
2. The role of mast cells in the defence against pathogens10.1371/journal.ppat.1002619 ↗
3. Mast cells in autoimmune disease10.1038/nature01324 ↗
4. IgE and mast cells in allergic disease10.1038/nm.2755 ↗
5. Mast cells and angiogenesis in multiple sclerosis10.1007/s00011-020-01394-2 ↗
6. Mast cells in early rheumatoid arthritis associate with disease severity and support B cell autoantibody production10.1136/annrheumdis-2018-213418 ↗
7. Relationship of small airway chymase-positive mast cells and lung function in severe asthma10.1164/rccm.200407-949OC ↗
8. Increased expression of mast cell chymase in the lungs of patients with congenital heart disease associated with early pulmonary vascular disease10.1164/ajrccm.160.4.9810058 ↗
9. Quantitative analysis of tryptase- and chymase-containing mast cells in atopic dermatitis and nummular eczema10.1111/j.1365-2133.1997.tb03927.x ↗
10. Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis10.1016/j.jaci.2015.01.033 ↗
11. The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch10.1016/j.jid.2017.12.029 ↗
12. Atopic dermatitis skin biopsies have high numbers of activated mast cells that are inhibited by AK002 after stimulation ex vivo10.1016/j.jaci.2019.12.293 ↗
13. Mast cells are locally activated and respond to MRGPRX2 stimulation in atopic dermatitis ex vivo skin biopsies10.1016/j.jaci.2021.12.058 ↗
14. Mast cell subpopulations in the synovial tissue of patients with osteoarthritis: selective increase in numbers of tryptase-positive, chymase- negative mast cells10.1002/(SICI)1096-9896(199809)186:1<67::AID-PATH132>3.0.CO;2-D ↗
15. Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions10.1002/(SICI)1097-0215(19970729)72:3<385::AID-IJC1>3.0.CO;2-L ↗
16. The relationship of tryptase- and chymase-positive mast cells to angiogenesis in stage I non-small cell lung cancer10.1016/j.ejcts.2005.06.020 ↗
17. Mast cell secretory granules: armed for battle10.1038/nri3690 ↗
18. New developments in mast cell biology10.1038/ni.f.216 ↗
19. Mast cell mediators: their differential release and the secretory pathways involved10.3389/fimmu.2014.00569 ↗
20. Mast cells in the development of adaptive immune responses10.1038/ni1158 ↗
21. Integrated signalling pathways for mast-cell activation10.1038/nri1782 ↗
22. Extracellular superoxide released from mitochondria mediates mast cell death by advanced glycation end products10.1016/j.bbamcr.2008.08.010 ↗
23. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions10.1038/nature14022 ↗
24. Identification of short peptide sequences that activate human mast cells via mas-related g-protein coupled receptor member x210.1016/j.actbio.2021.09.011 ↗
25. Estrogen inhibits mast cell chymase release to prevent pressure overload-induced adverse cardiac remodeling10.1161/HYPERTENSIONAHA.114.04238 ↗
26. The autocrine role of tryptase in pressure overload-induced mast cell activation, chymase release and cardiac fibrosis10.1016/j.ijcme.2015.11.003 ↗
27. SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury10.1038/s41392-021-00849-0 ↗
28. Adverse roles of mast cell chymase-1 in chronic obstructive pulmonary disease10.1183/13993003.01431-2021 ↗
29. Epigallocatechin-3-gallate induces cytokine production in mast cells by stimulating an extracellular superoxide-mediated calcium influx10.1016/j.bcp.2011.09.011 ↗
30. Reactive oxygen species produced up- or downstream of calcium influx regulate proinflammatory mediator release from mast cells: role of NADPH oxidase and mitochondria10.1016/j.bbamcr.2007.12.004 ↗
31. Mast cells as sources of cytokines, chemokines, and growth factors10.1111/imr.12634 ↗
32. Human mast cell-derived gelatinase B (matrix metalloproteinase-9) is regulated by inflammatory cytokines: role in cell migration10.4049/jimmunol.177.4.2638 ↗
33. Human mast cells produce matrix metalloproteinase 910.1002/(SICI)1521-4141(199908)29:08<2645::AID-IMMU2645>3.0.CO;2-1 ↗
34. Upregulation of Mas-related G Protein coupled receptor X2 in asthmatic lung mast cells and its activation by the novel neuropeptide hemokinin-110.1186/s12931-017-0698-3 ↗
35. Activationinduced upregulation of MMP9 in mast cells is a positive feedback mediator for mast cell activation10.3892/mmr.2017.6215 ↗
36. Self-assembling peptide nanoscaffold that activates human mast cells10.1021/acsami.7b14560 ↗
37. Immunologic release of β-hexosaminidase and β-glucuronidase from purified rat serosal mast cells10.4049/jimmunol.123.4.1445 ↗
38. Ige-mediated mast cell degranulation and recovery monitored by time-lapse photography10.1067/mai.2001.116124 ↗
39. Acid hydrolases and tryptase from secretory granules of dispersed human lung mast cells10.4049/jimmunol.126.4.1290 ↗
40. Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, mono-mac-6 cells, and human skin-derived mast cells10.4049/jimmunol.170.11.5667 ↗
41. Altered expression of mast cell chymase and tryptase and of c-kit in human cutaneous scar tissue10.1046/j.1523-1747.2000.00837.x ↗
42. Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells10.4049/jimmunol.138.8.2611 ↗
43. Chymase-positive mast cells play a role in the vascular component of airway remodeling in asthma10.1016/j.jaci.2007.04.021 ↗
44. Alterations in lung mast cell populations in patients with chronic obstructive pulmonary disease10.1164/rccm.200906-0932OC ↗
45. Gelatinase B/MMP-9 as an inflammatory marker enzyme in mouse zymosan peritonitis: comparison of phase-specific and cell-specific production by mast cells, macrophages and neutrophils10.1016/j.imbio.2007.07.005 ↗
46. Mast cell MMP-9 production enhanced by bacterial lipopolysaccharide10.1292/jvms.63.811 ↗
47. Rodent and human mast cells produce functionally significant intracellular reactive oxygen species but not nitric oxide10.1074/jbc.M409738200 ↗
48. The phosphoinositide 3-kinase-dependent activation of Btk is required for optimal eicosanoid production and generation of reactive oxygen species in antigen-stimulated mast cells10.4049/jimmunol.181.11.7706 ↗
49. FcεRI- and Fcγ receptor-mediated production of reactive oxygen species by mast cells is lipoxygenase- and cyclooxygenase-dependent and NADPH oxidase-independent10.4049/jimmunol.179.10.7059 ↗
50. FcεRI signaling of mast cells activates intracellular production of hydrogen peroxide: role in the regulation of calcium signals10.4049/jimmunol.171.11.6119 ↗
51. Discrete generations of intracellular hydrogen peroxide and superoxide in antigen-stimulated mast cells: reciprocal regulation of store-operated Ca2+ channel activity10.1016/j.molimm.2009.04.013 ↗
52. Silver activates mast cells through reactive oxygen species production and a thiol-sensitive store-independent Ca2+ influx10.1016/j.freeradbiomed.2006.01.023 ↗
53. Galectin-3 but not galectin-1 induces mast cell death by oxidative stress and mitochondrial permeability transition10.1016/j.bbamcr.2008.01.025 ↗
54. Enzymes of the mast cell granule10.1111/1523-1747.ep12543620 ↗
55. Expression of α-tryptase and β-tryptase by human basophils10.1016/j.jaci.2004.02.032 ↗
56. Two types of human mast cells that have distinct neutral protease compositions10.1073/pnas.83.12.4464 ↗
57. Mast cell phenotype, location, and activation in severe asthma: data from the Severe Asthma Research Program10.1164/rccm.201002-0295OC ↗
58. R. Zhang, V.L.Y. Yip, S.G. Withers, Mechanisms of enzymatic glycosyl transfer, (2010).10.1016/B978-008045382-8.00167-2 ↗
59. Does β-hexosaminidase function only as a degranulation indicator in mast cells? The primary role of β-hexosaminidase in mast cell granules10.4049/jimmunol.1302520 ↗
60. Role for lysosomal enzyme β-hexosaminidase in the control of mycobacteria infection10.1073/pnas.0708110105 ↗
61. Mast cells are critical for controlling the bacterial burden and the healing of infected wounds10.1073/pnas.1908816116 ↗
62. Novel β-N-acetylglucosaminidases from Vibrio harveyi 650: cloning, expression, enzymatic properties, and subsite identification10.1186/1471-2091-11-40 ↗
63. Characterization of β-N-acetylhexosaminidase (LeHex20A), a member of glycoside hydrolase family 20, from Lentinula edodes (shiitake mushroom)10.1186/2191-0855-2-29 ↗
64. A novel β-N-acetyl-d-hexosaminidase from the insect Ostrinia furnacalis (Guenée)10.1111/j.1742-4658.2008.06695.x ↗
65. Chitooligosaccharides are converted to N-acetylglucosamine by N-acetyl-β-hexosaminidase from stenotrophomonas maltophilia10.1111/1574-6968.12237 ↗
66. The chitin catabolic cascade in the marine bacterium vibrio furnissii: molecular cloning, isolation, and characterization of a periplasmic β-N-acetylglucosaminidase10.1074/jbc.271.52.33425 ↗
67. Purification and characterization of an Exo-β-D-glucosaminidase, a novel type of enzyme, from nocardia orientalis10.1016/S0021-9258(19)38783-6 ↗
68. Hyaluronidase 1 and β-hexosaminidase have redundant functions in hyaluronan and chondroitin sulfate degradation10.1074/jbc.M112.350447 ↗
69. In vitro and in vivo degradation behavior of acetylated chitosan porous beads10.1163/156856208783719482 ↗
70. Chitooligosaccharides and their biological activities: a comprehensive review10.1016/j.carbpol.2017.12.067 ↗
71. High throughput substrate specificity profiling of serine and cysteine proteases using solution-phase fluorogenic peptide microarrays10.1074/mcp.M500004-MCP200 ↗
72. Structural basis of substrate specificity in the serine proteases10.1002/pro.5560040301 ↗
73. Definition of the extended substrate specificity determinants for β-tryptases I and II10.1074/jbc.M102997200 ↗
74. The influence of substrate peptide length on human β-tryptase specificity10.1002/psc.1026 ↗
75. Synthesis and physical characterization of a P1 arginine combinatorial library, and its application to the determination of the substrate specificity of serine peptidases10.1016/S0968-0896(02)00174-8 ↗
76. Human pituitary tryptase: molecular forms, NH2-terminal sequence, immunocytochemical localization, and specificity with prohormone and fluorogenic substrates10.1016/S0021-9258(19)75795-0 ↗
77. Substrate specificity and inhibitory study of human airway trypsin-like protease10.1016/j.bmc.2010.06.059 ↗
78. Mammalian tissue trypsin-like enzymes10.1016/S0021-9258(17)43949-4 ↗
79. Human cytotoxic lymphocyte tryptase. Its purification from granules and the characterization of inhibitor and substrate specificity10.1016/S0021-9258(18)37694-4 ↗
80. Albumin is a substrate, of human chymase: prediction by combinatorial peptide screening and development of a selective inhibitor based on the albumin cleavage site10.1074/jbc.M304087200 ↗
81. Inhibitors of human heart chymase based on a peptide library10.1073/pnas.92.15.6738 ↗
82. Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase from the human heart10.1016/S0021-9258(18)54981-4 ↗
83. Distinct multisite synergistic interactions determine substrate specificities of human chymase and rat chymase-1 for angiotensin II formation and degradation10.1074/jbc.272.5.2963 ↗
84. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart10.1016/S0021-9258(18)45712-2 ↗
85. Mast cell peptidases (carboxypeptidase A and chymase)-mediated hydrolysis of human angiotensin-(1–12) substrate10.1016/j.bbrc.2019.08.098 ↗
86. The extended substrate specificity of the human mast cell chymase reveals a serine protease with well-defined substrate recognition profile10.1093/intimm/dxn128 ↗
87. Mammalian chymotrypsin-like enzymes. Comparative reactivities of rat mast cell proteases, human and dog skin chymases, and human cathepsin G with peptide 4-nitroanilide substrates and with peptide chloromethyl ketone and sulfonyl fluoride inhibitors10.1021/bi00329a037 ↗
88. Discriminating between the activities of human cathepsin G and chymase using fluorogenic substrates10.1111/j.1742-4658.2011.08189.x ↗
89. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators10.1165/ajrcmb.20.3.3311 ↗
90. Inhibition of gelatinase B (matrix metalloprotease-9) activity reduces cellular inflammation and restores function of transplanted pancreatic islets10.2337/db11-1143 ↗
91. Renal clearable catalytic gold nanoclusters for in vivo disease monitoring10.1038/s41565-019-0527-6 ↗
92. Uncontrolled gelatin degradation in non-healing chronic wounds10.12968/jowc.2018.27.11.724 ↗
93. Active site specificity profiling of the matrix metalloproteinase family: proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses10.1016/j.matbio.2015.09.003 ↗
94. Basis for substrate recognition and distinction by matrix metalloproteinases10.1073/pnas.1406134111 ↗
95. Substrate hydrolysis by matrix metalloproteinase-910.1074/jbc.M100900200 ↗
96. Enzyme-responsive nanoparticles for targeted accumulation and prolonged retention in heart tissue after myocardial infarction10.1002/adma.201502003 ↗
97. Bioresponsive mesoporous silica nanoparticles for triggered drug release10.1021/ja206998x ↗
98. Matrix metalloproteinase-9 (MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer10.1016/j.jconrel.2016.08.016 ↗
99. Gelatin carriers for drug and cell delivery in tissue engineering10.1016/j.jconrel.2014.04.014 ↗
100. Recombinant collagen and gelatin for drug delivery10.1016/j.addr.2003.08.008 ↗